Tengion Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
40
- Stock Symbol
-
TNGNQ
Tengion General Information
Description
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.
Contact Information
Website
www.tengion.comCorporate Office
- 3929 Westpoint Boulevard
- Suite G
- Winston-Salem, NC 27103
- United States
Corporate Office
- 3929 Westpoint Boulevard
- Suite G
- Winston-Salem, NC 27103
- United States
Tengion Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 1.06K |
Tengion Financials Summary
As of 30-Sep-2014, Tengion has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2014 | FY 2013 31-Dec-2013 | FY 2012 31-Dec-2012 | FY 2011 31-Dec-2011 |
|---|---|---|---|---|
| EV | 21,804 | 2,588 | 6,175 | (2,938) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (56,419) | (11,085) | (13,543) | (15,124) |
| Net Income | (64,426) | (18,927) | (16,929) | (19,061) |
| Total Assets | 9,621 | 25,724 | 12,435 | 17,817 |
| Total Debt | 34,122 | 26,952 | 11,269 | 4,987 |
Tengion Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tengion Comparisons
Industry
Financing
Details
Tengion Competitors (3)
One of Tengion’s 3 competitors is Mimedx Group, a Corporation company based in Marietta, GA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mimedx Group | Corporation | Marietta, GA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Cerenome | Corporation | Houston, TX |
Tengion Patents
Tengion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2014182885-A2 | Organoids comprising isolated renal cells and uses thereof | Inactive | 08-May-2013 | ||
| WO-2014182885-A3 | Organoids comprising isolated renal cells and uses thereof | Inactive | 08-May-2013 | ||
| US-20250152632-A1 | Renal cell populations and uses thereof | Pending | 24-Oct-2012 | ||
| WO-2014066699-A1 | Renal cell populations and uses thereof | Inactive | 24-Oct-2012 | ||
| WO-2013067498-A1 | Drug screening and potency assays | Inactive | 04-Nov-2011 | G01N33/5082 |
Tengion Signals
Tengion FAQs
-
When was Tengion founded?
Tengion was founded in 2003.
-
Where is Tengion headquartered?
Tengion is headquartered in Winston-Salem, NC.
-
What is the size of Tengion?
Tengion has 40 total employees.
-
What industry is Tengion in?
Tengion’s primary industry is Biotechnology.
-
Is Tengion a private or public company?
Tengion is a Public company.
-
What is Tengion’s stock symbol?
The ticker symbol for Tengion is TNGNQ.
-
Who are Tengion’s competitors?
Mimedx Group, Genentech, and Cerenome are competitors of Tengion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process